NYSE:LCI - Lannett Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.55 -0.15 (-1.02 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$14.70
Today's Range$14.25 - $14.85
52-Week Range$13.15 - $30.35
Volume587,100 shs
Average Volume715,061 shs
Market Capitalization$558.81 million
P/E Ratio5.09
Dividend YieldN/A
Beta2.51
Lannett logoLannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It also provides its products for various medical indications comprising glaucoma, cholesterol, muscle spasm, migraine, pain management, cardiovascular, antipsychosis, gastrointestinal, urinary, bronchospasms, respiratory, gallstone, congestive heart failure, thyroid deficiency, central nervous system, and gout. In addition, the company manufactures active pharmaceutical ingredients; and markets its products under the Diamox, Lipitor, Lioresal, Fioricet, Fiorinal, Lanoxin, Prolixin, MiraLAX, Imdur, Levoxyl/Synthroid, Metadate CD, Concerta, Procardia, Prilosec, Ditropan, Protonix, Imitrex, Brethine, Tussionex, and Actigall brands. Further, it sells pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with JSP, Summit Bioscience LLC, HEC Pharm Group, and Pharma Pass II LLC. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.

Receive LCI News and Ratings via Email

Sign-up to receive the latest news and ratings for LCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:LCI
CUSIP51601210
Phone215-333-9000

Debt

Debt-to-Equity Ratio1.29
Current Ratio2.56
Quick Ratio1.91

Price-To-Earnings

Trailing P/E Ratio5.09
Forward P/E Ratio4.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$633.34 million
Price / Sales0.87
Cash Flow$4.3433 per share
Price / Cash3.35
Book Value$15.07 per share
Price / Book0.97

Profitability

EPS (Most Recent Fiscal Year)$2.86
Net Income$-580,000.00
Net Margins7.01%
Return on Equity18.64%
Return on Assets6.73%

Miscellaneous

Employees1,126
Outstanding Shares38,010,000

Lannett (NYSE:LCI) Frequently Asked Questions

What is Lannett's stock symbol?

Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

How were Lannett's earnings last quarter?

Lannett Company, Inc. (NYSE:LCI) announced its quarterly earnings results on Monday, May, 7th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.76 by $0.04. The company earned $174.39 million during the quarter, compared to analyst estimates of $176.51 million. Lannett had a return on equity of 18.64% and a net margin of 7.01%. The firm's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.77 EPS. View Lannett's Earnings History.

When is Lannett's next earnings date?

Lannett is scheduled to release their next quarterly earnings announcement on Tuesday, August, 21st 2018. View Earnings Estimates for Lannett.

What price target have analysts set for LCI?

5 Wall Street analysts have issued 12 month price targets for Lannett's stock. Their predictions range from $19.00 to $25.00. On average, they anticipate Lannett's stock price to reach $21.50 in the next year. View Analyst Ratings for Lannett.

Who are some of Lannett's key competitors?

Who are Lannett's key executives?

Lannett's management team includes the folowing people:
  • Mr. Martin P. Galvan CPA, VP of Fin., CFO & Treasurer (Age 66)
  • Mr. Robert Ehlinger, VP of Logistics & Chief Information Officer (Age 61)
  • Mr. Kevin R. Smith, Sr. VP of Sales & Marketing (Age 58)
  • Mr. John M. Abt, VP of Quality (Age 53)
  • Mr. Arthur P. Bedrosian, Director (Age 72)

Has Lannett been receiving favorable news coverage?

Media headlines about LCI stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lannett earned a media sentiment score of 0.19 on Accern's scale. They also assigned media stories about the company an impact score of 46.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Lannett's major shareholders?

Lannett's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.59%), LSV Asset Management (5.44%), Frontier Capital Management Co. LLC (2.59%), Dimensional Fund Advisors LP (2.17%), Northern Trust Corp (2.12%) and Heartland Advisors Inc. (1.61%). Company insiders that own Lannett stock include Arthur P Bedrosian, David Farber, G Michael Landis, James M Maher, Kevin Smith, Patrick G Lepore, Robert Ehlinger and Timothy C Crew. View Institutional Ownership Trends for Lannett.

Which institutional investors are selling Lannett stock?

LCI stock was sold by a variety of institutional investors in the last quarter, including Muhlenkamp & Co. Inc., Federated Investors Inc. PA, Point72 Asset Management L.P., SG Americas Securities LLC, Barclays PLC, CLARET ASSET MANAGEMENT Corp, Dimensional Fund Advisors LP and Cubist Systematic Strategies LLC. Company insiders that have sold Lannett company stock in the last year include Arthur P Bedrosian, David Farber and Kevin Smith. View Insider Buying and Selling for Lannett.

Which institutional investors are buying Lannett stock?

LCI stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Northern Trust Corp, KBC Group NV, Heartland Advisors Inc., BlackRock Inc., Frontier Capital Management Co. LLC, Russell Investments Group Ltd. and Mackay Shields LLC. Company insiders that have bought Lannett stock in the last two years include Arthur P Bedrosian, Patrick G Lepore and Timothy C Crew. View Insider Buying and Selling for Lannett.

How do I buy shares of Lannett?

Shares of LCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lannett's stock price today?

One share of LCI stock can currently be purchased for approximately $14.55.

How big of a company is Lannett?

Lannett has a market capitalization of $558.81 million and generates $633.34 million in revenue each year. The company earns $-580,000.00 in net income (profit) each year or $2.86 on an earnings per share basis. Lannett employs 1,126 workers across the globe.

How can I contact Lannett?

Lannett's mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company can be reached via phone at 215-333-9000.


MarketBeat Community Rating for Lannett (LCI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  354 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  627
MarketBeat's community ratings are surveys of what our community members think about Lannett and other stocks. Vote "Outperform" if you believe LCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.